AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10203118 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention)
Number of subjects: 267
Study 7772420 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (NIDDM)
Number of subjects: 40
Study 7772420 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Non-diabetic control)
Number of subjects: 40
Study 7772420 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia (NIDDM)
Number of subjects: 40
Study 7772420 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia (Non-diabetic control)
Number of subjects: 40
Study 2372525 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 12
Study 2372525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6107932 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl (40 mg i.m. 3-times for 6 days)
Number of subjects: 32
Study 6107932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 30075569 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600)
Number of subjects: 0
Study 30075569 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 0.25 mcg
Number of subjects: 0
Study 25942016 — intervention group
Group type: EXPERIMENTAL
Intervention: Power capacities (Sargent-jump, broad-jump, medicine-ball-throw)
Number of subjects: 92
Study 25942016 — intervention group
Group type: EXPERIMENTAL
Intervention: Zig-zag-Test
Number of subjects: 92
Study 25942016 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric indices
Number of subjects: 92
Study 25942016 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility performance tests (T-Shape-Test, Zig-Zag-Test, T180)
Number of subjects: 92
Study 26091817 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) using right unilateral or bitemporal electrode placement and brief or ultrabrief pulse width, administered 3 times per week.
Number of subjects: 74
Study 23782581 — intervention group
Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.125% plus fentanyl 4 μg ml‐1 (Group F)
Number of subjects: 40
Study 23782581 — intervention group
Group type: COMPARATOR
Intervention: levobupivacaine 0.125% (Group L)
Number of subjects: 40
Study 19028835 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental (GABA(A) receptor agonist)
Number of subjects: 28
Study 19028835 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (NMDA receptor antagonist)
Number of subjects: 28
Study 19028835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: Venturi system (Starmed) with helmet
Number of subjects: 8
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: Venturi system (Starmed) with face-mask
Number of subjects: 8
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisperflow-2 system (Caradyne Ltd) with helmet
Number of subjects: 8
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: CF800 system (Drägerwerk, AG) with helmet
Number of subjects: 8
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: CF800 system (Drägerwerk, AG) with face-mask
Number of subjects: 8
Study 17996003 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilator (Servoventilator 300, Siemens-Elema) with face-mask
Number of subjects: 8
Study 15941413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 438
Study 15941413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus amodiaquine (SP + AQ)
Number of subjects: 438
Study 15941413 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus artesunate (SP + AS)
Number of subjects: 438
Study 12917861 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (20g/d for 5 days)
Number of subjects: 16
Study 12917861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10593713 — intervention group
Group type: EXPERIMENTAL
Intervention: Contracted blood sampling protocol (6 samples over 8 hours)
Number of subjects: 0
Study 10593713 — intervention group
Group type: COMPARATOR
Intervention: Extended blood sampling schedule (15 samples over 48 hours)
Number of subjects: 0
Study 8606561 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrantectomy plus axillary dissection and radiotherapy (QUART)
Number of subjects: 1760
Study 8606561 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 1760
Study 1743767 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-type whole-body vibration with varying amplitude and number of shocks
Number of subjects: 17
Study 1743767 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 7022531 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 1.6 mg
Number of subjects: 13
Study 7022531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 30967272 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (hands-on training)
Number of subjects: 298
Study 30967272 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hands-on training)
Number of subjects: 298
Study 30967272 — intervention group
Group type: COMPARATOR
Intervention: Pre-test knowledge assessment
Number of subjects: 298
Study 28506447 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 55
Study 28506447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 25646296 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 0
Study 25646296 — intervention group
Group type: COMPARATOR
Intervention: Azilsartan 20 mg
Number of subjects: 0
Study 23279193 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (gabapentin 300 mg, tramadol 50 mg TDS, methylcobalamin 500 μgm PO)
Number of subjects: 30
Study 23279193 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral glossopharyngeal nerve block with standard medical therapy
Number of subjects: 30
Study 23279193 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (gabapentin, tramadol, methylcobalamin)
Number of subjects: 30
Study 21085001 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel loading dose
Number of subjects: 84
Study 21085001 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel loading dose
Number of subjects: 84
Study 21085001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (600 mg and 300 mg clopidogrel)
Number of subjects: 84
Study 19011955 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAP (Comprehensive Muscular Activity Profile)
Number of subjects: 80
Study 19011955 — intervention group
Group type: COMPARATOR
Intervention: Therapists' ratings
Number of subjects: 80
Study 19011955 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAP combined with therapists' ratings
Number of subjects: 80
Study 17579942 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg for 2 weeks
Number of subjects: 368
Study 17579942 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy
Number of subjects: 368
Study 17579942 — intervention group
Group type: COMPARATOR
Intervention: PPI strategy
Number of subjects: 368
Study 15385381 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-injection (Group 1)
Number of subjects: 75
Study 15385381 — intervention group
Group type: COMPARATOR
Intervention: Dual-injection (Group 2)
Number of subjects: 75
Study 15385381 — intervention group
Group type: COMPARATOR
Intervention: Triple-injection (Group 3)
Number of subjects: 75
Study 11306155 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different antiretroviral strategies
Number of subjects: 0
Study 9642898 — intervention group
Group type: COMPARATOR
Intervention: Brief advice
Number of subjects: 40
Study 9642898 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interview
Number of subjects: 40
Study 8124794 — intervention group
Group type: EXPERIMENTAL
Intervention: RV‐‐>CAN (unipolar defibrillation system)
Number of subjects: 15
Study 8124794 — intervention group
Group type: COMPARATOR
Intervention: RV‐‐>SVC + CAN (three‐electrode dual pathway system)
Number of subjects: 15
Study 2570100 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive method (posters and pamphlets) in group B
Number of subjects: 9
Study 2570100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active method (in-service lectures) in group C
Number of subjects: 9
Study 2570100 — intervention group
Group type: EXPERIMENTAL
Intervention: Active method (in-service lectures) in group C after 6 months
Number of subjects: 9
Study 2570100 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive method (posters and pamphlets) in group B after 6 months
Number of subjects: 9
Study 2570100 — intervention group
Group type: COMPARATOR
Intervention: Simple announcement in group A (control)
Number of subjects: 9
Study 786302 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocromen
Number of subjects: 100
Study 786302 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 100
Study 31712614 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 56
Study 31712614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 30540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal acoustic reflectometry
Number of subjects: 80
Study 30540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast rate anal acoustic reflectometry (5 cm H2O/1 s)
Number of subjects: 80
Study 30540659 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal rate anal acoustic reflectometry (5 cm H2O/3 s)
Number of subjects: 80
Study 30540659 — intervention group
Group type: COMPARATOR
Intervention: Manometry
Number of subjects: 80
Study 28599628 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab after disease progression
Number of subjects: 0
Study 28599628 — intervention group
Group type: COMPARATOR
Intervention: FOLFOXIRI plus bevacizumab followed by re-introduction of the same regimen after disease progression
Number of subjects: 0
Study 25716658 — intervention group
Group type: EXPERIMENTAL
Intervention: NexGard®
Number of subjects: 24
Study 25716658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bravecto™
Number of subjects: 24
Study 25716658 — intervention group
Group type: COMPARATOR
Intervention: NexGard® vs Bravecto™
Number of subjects: 24
Study 23747935 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy exercise program (two 30‐min sessions per week for 14 weeks)
Number of subjects: 19
Study 23747935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 19
Study 21300923 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 350
Study 21300923 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 350
Study 19322527 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17121210 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 3000
Study 17121210 — intervention group
Group type: COMPARATOR
Intervention: Insulin isophane
Number of subjects: 3000
Study 17121210 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 3000
Study 14692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Autohaler
Number of subjects: 200
Study 14692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler
Number of subjects: 200
Study 11572420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination protocol with follow-up contacts (5 postcards, 10 phone calls, 3 home visits)
Number of subjects: 85
Study 9039333 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (2 IU/m2 per day)
Number of subjects: 29
Study 9039333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1406395 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (colestipol 5 g or 10 g + simvastatin 20 mg/night then 40 mg/night)
Number of subjects: 61
Study 1406395 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 61
Study 3966330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide
Number of subjects: 100
Study 3966330 — intervention group
Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 100
Study 3966330 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 100
Study 3966330 — intervention group
Group type: COMPARATOR
Intervention: Other antiarrhythmic drug regimens
Number of subjects: 100
Study 30172724 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2.5 mA)
Number of subjects: 0
Study 30172724 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (34 μA)
Number of subjects: 0
Study 27332627 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal Rivastigmine
Number of subjects: 0
Study 27332627 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed model for C8h, C12h, and C18h
Number of subjects: 0
Study 25180379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry capsules
Number of subjects: 928
Study 25180379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 928
Study 23033347 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5599
Study 23033347 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 5599
Study 20620411 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Gy prophylactic radiotherapy before bicalutamide
Number of subjects: 125
Study 20620411 — intervention group
Group type: COMPARATOR
Intervention: Bicalutamide only (nonprophylactic)
Number of subjects: 125
Study 18689589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT) for SDB in obese children
Number of subjects: 70
Study 18689589 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT) for SDB in nonobese children
Number of subjects: 70
Study 16044793 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12004993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (88 microg [2 puffs of 44 microg] twice daily)
Number of subjects: 522
Study 12004993 — intervention group
Group type: COMPARATOR
Intervention: Montelukast (10 mg/d)
Number of subjects: 522
Study 10464834 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled ceftazidime and tobramycin (group A)
Number of subjects: 15
Study 10464834 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment (group B)
Number of subjects: 15
Study 7853037 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic meta-analysis
Number of subjects: 0
Study 7853037 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory meta-analysis
Number of subjects: 0
Study 2240724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg IV bolus, followed by 2 mg/min IV drip, with a second bolus of 0.5 mg/kg after 10 minutes)
Number of subjects: 1427
Study 2240724 — intervention group
Group type: COMPARATOR
Intervention: Control (no lidocaine treatment)
Number of subjects: 1427
Study 2240724 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1427
Study 2240724 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1427
Study 350499 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg indomethacin plus 10 mg diazepam
Number of subjects: 18
Study 350499 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulindac
Number of subjects: 18
Study 350499 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg sulindac plus 10 mg diazepam
Number of subjects: 18
Study 6752070 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate nasal spray (400 micrograms daily)
Number of subjects: 70
Study 6752070 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 70
Study 29993815 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for predicting sigma‐54 promoters using motif finding and machine learning strategies
Number of subjects: 0
Study 29993815 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for predicting sigma‐54 promoters
Number of subjects: 0
Study 29225003 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM (Respiratory Volume Monitor)
Number of subjects: 73
Study 29225003 — intervention group
Group type: COMPARATOR
Intervention: Control (no access to RVM data)
Number of subjects: 73
Study 29225003 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM rated as 'not useful'
Number of subjects: 73
Study 29225003 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM rated as 'somewhat useful'
Number of subjects: 73
Study 29225003 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM rated as 'very useful'
Number of subjects: 73
Study 27444687 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted case-finding group
Number of subjects: 74818
Study 27444687 — intervention group
Group type: EXPERIMENTAL
Intervention: Active case-finding group
Number of subjects: 74818
Study 27444687 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic case-finding group
Number of subjects: 74818
Study 27444687 — intervention group
Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 74818
Study 27444687 — intervention group
Group type: COMPARATOR
Intervention: Active case-finding vs Opportunistic case-finding
Number of subjects: 74818
Study 27444687 — intervention group
Group type: COMPARATOR
Intervention: Cost-effectiveness of Active vs Opportunistic case-finding
Number of subjects: 74818
Study 25265284 — intervention group
Group type: COMPARATOR
Intervention: Intranasal insulin (40 IU)
Number of subjects: 54
Study 25265284 — intervention group
Group type: COMPARATOR
Intervention: Oral cortisol (30 mg)
Number of subjects: 54
Study 25265284 — intervention group
Group type: COMPARATOR
Intervention: Both intranasal insulin and oral cortisol
Number of subjects: 54
Study 25265284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 22464310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA (50 U, 100 U, 150 U, 200 U, or 300 U)
Number of subjects: 313
Study 22464310 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA (doses ≥100 U)
Number of subjects: 313
Study 22464310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study 21061865 — intervention group
Group type: EXPERIMENTAL
Intervention: Stages‐of‐change motivational interviewing (SOCMI)
Number of subjects: 528
Study 21061865 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy gender reeducation (CBTGR)
Number of subjects: 528
Study 17647298 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20‐60 mg/day) for 6 weeks
Number of subjects: 100
Study 17647298 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (50‐150 mg/day) for 6 weeks
Number of subjects: 100
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg per day
Number of subjects: 224
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification counseling alone
Number of subjects: 224
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus lifestyle modification counseling (combined therapy)
Number of subjects: 224
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine plus brief lifestyle modification counseling
Number of subjects: 224
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with frequent food intake recording
Number of subjects: 224
Study 16291981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with infrequent food intake recording
Number of subjects: 224
Study 12077767 — intervention group
Group type: COMPARATOR
Intervention: IL-1ra
Number of subjects: 34
Study 12077767 — intervention group
Group type: COMPARATOR
Intervention: IL-6
Number of subjects: 34
Study 12077767 — intervention group
Group type: COMPARATOR
Intervention: TNF-alpha
Number of subjects: 34
Study 9801481 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 33
Study 9801481 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 33
Study 8749868 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (8 mmol over 5 min followed by 65 mmol over 24 h)
Number of subjects: 78
Study 8749868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8749868 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 78
Study 2708970 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and response prevention of bingeing (ERPB)
Number of subjects: 11
Study 2708970 — intervention group
Group type: COMPARATOR
Intervention: Exposure and response prevention of vomiting (ERPV)
Number of subjects: 11
Study 732289 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-hour training programs
Number of subjects: 55
Study 732289 — intervention group
Group type: COMPARATOR
Intervention: Other human services curricula
Number of subjects: 55
Study 31053213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension for 2 weeks (mean sleep duration 396 [25] minutes, extended by 60.1 [28.5] minutes)
Number of subjects: 21
Study 31053213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension for 2 weeks
Number of subjects: 21
Study 29103081 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 77
Study 29103081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 26499057 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTIVATE™ computer program, used at home for 40 minutes per day, 6 days per week for 8 weeks.
Number of subjects: 122
Study 26499057 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control group).
Number of subjects: 122
Study 23803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study 23803951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (Holter substudy)
Number of subjects: 6505
Study 21254911 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (RLX) 60 mg daily
Number of subjects: 135